Incyte Genomics Inc

$114.63$-1.25 (-1.08%)
Last updated on --.

Incyte Genomics Inc price

24 Hours-1.08%-$1.250
30 days-1.97%-$2.305
60 days-9.69%-$12.31
90 days-10.44%-$13.36

About Incyte Genomics Inc

Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.

Stock ticker
INCY
Company
Incyte Corporation
Industry
Healthcare
Category
US
Stock split / reverse split
12
Launch date
Nov 4, 1993
Listed exchange
NASDAQ

Financials

Q3 FY2026 Earnings
Report period: Jul 1, 2026 – Sep 30, 2026

Summary: INCY reported Revenue of 1.56B (+14.00%), beating expectations; EPS of -3.60 (-259.29%), beating expectations.

Revenue (USD)Beat1.56B+13.99%1.46B+8.15%92.48M+6.31%
EPS (USD)Beat-3.60-259.30%-3.93-336.75%0.33+8.39%
Financial estimates
● Actual● Estimate
Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
2.111.461.472.81-3.86
+290.74%+43.13%+83.75%+37.74%-282.94%
● EPS● YoY
Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
6.33B6.96B7.34B7.87B7.29B
1.68B1.79B1.79B1.53B1.64B
26.52%25.73%24.34%19.41%22.56%
● Assets● Liabilities● Ratio
Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
559.39M543.30M369.35M507.66M-675.32M
+79.94%+42.51%+38.81%+1,034.66%-220.73%
● CFO● YoY

Shareholders

Shareholders
BAKER BROS. ADVISORS LP15.35%
Felix J. Baker15.31%
Julian C. Baker15.31%
BLACKROCK, INC.8.99%
DODGE & COX5.96%
Others39.04%
Institutions
% Owned102.63%+0.15%
Shares held204.60M+312.03K
Institutions880+39
% OwnedPrice
Name% OwnedChange
BAKER BROS. ADVISORS LP15.35%+17.92K
Felix J. Baker15.31%0.00
Julian C. Baker15.31%0.00
BLACKROCK, INC.8.99%-945.48K
DODGE & COX5.96%-295.03K

Dividends

Stock splits
Launch date: Nov 4, 1993
DateRatio
Sep 1, 20001 → 2
Nov 10, 19971 → 2

Incyte Genomics Inc conversion tables

INCYINCY
USDUSD
0.5 INCY57.31 USD
1 INCY114.62 USD
5 INCY573.12 USD
10 INCY1,146.25 USD
USDUSD
INCYINCY
0.5 USD0.0043621 INCY
1 USD0.0087241 INCY
5 USD0.043621 INCY
10 USD0.087241 INCY

More to explore

FAQ

INCY is trading at $114.63, -1.08% over the last 24 hours. Track live moves on the price chart at the top of this page.

The INCY stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. INCY is currently trading at $114.63, -1.08% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on INCY price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.

P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. INCY's P/E ratio is currently 61.97 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from INCY; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against INCY's historical range and other companies in the Healthcare sector.

Incyte Corporation's market cap is currently 23.75B USD. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.